Jessup's Strategic Portfolio Shifts
Jessup Wealth Management Adds Estee Lauder, Significantly Expands UnitedHealth and Other Holdings
Anonymous
Key Points
1
Jessup Wealth Management bought a new position in Estee Lauder, purchasing 60,405 shares worth about $6.326 million; the stock made up ~2.1% of Jessup’s holdings and was its 16th-largest position, per Jessup’s Form 13F.
2
For Equitable Holdings, Jessup increased its stake by 13.5% in the fourth quarter—buying an additional 17,023 shares to reach 143,071 shares—valued at about $6.817 million; Equitable was ~2.3% of the portfolio and Jessup’s 14th-largest holding.
3
Jessup’s UnitedHealth Group expansion was especially large: the firm grew its position by 1,849.1% to 26,800 shares (an increase of 25,425 shares), with the holding valued at about $8.847 million; UnitedHealth comprised ~2.9% of Jessup’s portfolio and ranked as its 11th-largest position.
4
In the SPDR Bloomberg High Yield Bond ETF (JNK), Jessup increased its stake by 5.8%—adding 7,229 shares to own 132,933 shares—valued at about $12.922 million; JNK was ~4.3% of the portfolio and Jessup’s 5th-largest position. The article also notes State Street boosted its own JNK stake by 14.2%, owning 12,662,802 shares valued at about $1.241 billion.
5
For Merck & Co., Jessup acquired 61,862 shares valued at roughly $6.512 million, representing about 2.2% of its holdings and making Merck its 15th-largest position; the article adds that hedge funds and other institutional investors own 76.07% of Merck’s stock.
Jessup Wealth Management Inc. made a dramatic bet on healthcare in its latest SEC filing, growing its UnitedHealth Group position by 1,849% — from 1,375 shares to 26,800 shares — valued at roughly $8.85 million, according to Watchlist News. The mid-tier wealth manager also initiated brand-new stakes in Estee Lauder and Merck & Co., signaling a broad shift away from growth stocks and toward value, dividends, and high-yield income.
The moves, disclosed through the firm's Form 13F filing with the SEC, paint a picture of a firm repositioning its clients toward blue-chip stability. JNK — the SPDR Bloomberg High Yield Bond ETF — now ranks as Jessup's 5th-largest holding, worth $12.92 million.
UnitedHealth Bet Dwarfs Every Other Move
The UnitedHealth Group expansion is the headline number. Jessup added 25,425 shares in the fourth quarter, an increase of 1,849.1%, according to Ticker Report. The firm now holds 26,800 shares worth about $8.85 million. That makes UnitedHealth Jessup's 11th-largest position, at 2.9% of the total portfolio.
Jessup was not alone. Ticker Report also noted that Wellspring Financial Advisors raised its own UnitedHealth stake by 292.7% in the same quarter. The pile-on from multiple managers suggests broad institutional conviction in the healthcare sector, even as regulatory pressure on pharmacy benefit managers remains a real risk.
New Estee Lauder Stake Is a Bold Recovery Bet
Jessup bought 60,405 shares of Estee Lauder in the fourth quarter — a brand-new position worth about $6.33 million, per Watchlist News. The stock now sits as the firm's 16th-largest holding, at roughly 2.1% of the portfolio. Estee Lauder has struggled with weak sales in Asian travel retail, making the entry a clear contrarian move.
At an implied price near $104 per share, Jessup is framing Estee Lauder as a value play on a premium brand. Several other institutional managers also initiated or boosted positions in EL during the same period, suggesting Jessup is not the only firm betting on a rebound in luxury consumer spending.
Merck and Equitable Round Out a Defensive Portfolio
Jessup also opened a fresh position in Merck & Co., buying 61,862 shares worth about $6.51 million. Merck is now the firm's 15th-largest holding at 2.2% of its portfolio, according to Watchlist News. Institutional investors as a group own 76.07% of Merck's total shares outstanding, leaving little room for retail investors to move the stock.
On Equitable Holdings, Jessup added 17,023 shares — a 13.5% increase — bringing its total to 143,071 shares valued at $6.82 million. Equitable is now Jessup's 14th-largest position at 2.3% of the book. Together, Merck and Equitable give the portfolio a steady, dividend-friendly anchor alongside the more aggressive healthcare and luxury plays.
High-Yield Bond ETF Signals a 'No Recession' Bet
Jessup lifted its stake in the SPDR Bloomberg High Yield Bond ETF — ticker JNK — by 5.8%, adding 7,229 shares to reach 132,933 total shares worth $12.92 million. JNK is now the firm's 5th-largest position at 4.3% of its portfolio. High-yield bond ETFs profit when corporate borrowers avoid default, so a bigger JNK stake signals confidence that a severe recession is not on the horizon.
Jessup has company in that call. State Street Global Advisors boosted its own JNK stake by 14.2% in the same period, bringing its holding to 12,662,802 shares worth about $1.24 billion, per Watchlist News. When one of the world's largest asset managers and a mid-tier wealth firm make the same move at the same time, the signal is hard to ignore.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
9
Reach
21
A
AnonymousAuthor
